Scientists from Harbin Medical University and Nantong Tumor Hospital develop integrative machine learning models combining gene co-expression analysis and multi-omics data to predict prostate cancer diagnosis and biochemical recurrence risk, enhancing personalized precision oncology.
Key points
- Applied WGCNA to identify 16 BCR-related genes and correlated modules with clinical recurrence outcomes in TCGA-PRAD.
- Constructed LASSO+LDA diagnostic model validated across five independent cohorts, achieving AUCs up to 0.897.
- Used XGBoost and SHAP analyses to pinpoint COMP as a high-impact biomarker and validated its functional role via molecular docking and in vivo assays.
Why it matters: Integrating machine learning with gene expression profiling enhances precision oncology by improving early detection and individualized recurrence risk assessment beyond conventional methods.
Q&A
- What is WGCNA?
- How does LASSO improve model building?
- Why is COMP important in prostate cancer?
- How is XGBoost used for biomarker discovery?